This article is more than 5 years old. Information may no longer be current.

Collaboration for prevention of type 2 diabetes recently announced

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Intrexon Corporation and Janssen Pharaceutica recently announced a collaboration to further develop ActoBiotics therapies for the treatment of type 2 diabetes, obesity and metabolic disorders related to energy dysregulation, according to a press release.

“I am very pleased we are partnering with Janssen to address type 2 diabetes and related conditions,” Samuel Broder, MD, senior vice president and head of Intrexon’s Health Sector, said in the release. “Through the use of Intrexon’s proprietary ActoBiotics platform, we believe this collaboration will make a significant contribution to this substantial global health issue. The breadth of opportunity to treat an array of diseases with our versatile ActoBiotics technology continues to expand.”

The ActoBiotics platform is used to engineer food-grade microbes, to be delivered orally to the gastrointestinal tract, that can express and secrete novel therapeutic proteins and peptides, according to the Intrexon website.

The Janssen-Intrexon collaboration will focus on diabetes prevention through halting progression of prediabetes.